These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30139575)

  • 21. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.
    Thorarensen A; Dowty ME; Banker ME; Juba B; Jussif J; Lin T; Vincent F; Czerwinski RM; Casimiro-Garcia A; Unwalla R; Trujillo JI; Liang S; Balbo P; Che Y; Gilbert AM; Brown MF; Hayward M; Montgomery J; Leung L; Yang X; Soucy S; Hegen M; Coe J; Langille J; Vajdos F; Chrencik J; Telliez JB
    J Med Chem; 2017 Mar; 60(5):1971-1993. PubMed ID: 28139931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of highly potent, selective, covalent inhibitors of JAK3.
    Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis.
    Yao H; Zhang J; Zheng Q; Zeng X; Huang H; Ling Z; Tang M; Chen Z; Wang W; He L
    Arch Pharm (Weinheim); 2024 Jun; 357(6):e2300753. PubMed ID: 38442328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
    Zhu Y; Zheng X; Wang C; Sun X; Sun H; Ma T; Li Y; Liu K; Chen L; Ma X
    Bioorg Med Chem; 2020 Jan; 28(2):115254. PubMed ID: 31866272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3.
    Nakajima Y; Aoyama N; Takahashi F; Sasaki H; Hatanaka K; Moritomo A; Inami M; Ito M; Nakamura K; Nakamori F; Inoue T; Shirakami S
    Bioorg Med Chem; 2016 Oct; 24(19):4711-4722. PubMed ID: 27544589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors.
    Bahekar R; Panchal N; Soman S; Desai J; Patel D; Argade A; Gite A; Gite S; Patel B; Kumar J; S S; Patel H; Sundar R; Chatterjee A; Mahapatra J; Patel H; Ghoshdastidar K; Bandyopadhyay D; Desai RC
    Bioorg Chem; 2020 Jun; 99():103851. PubMed ID: 32334196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
    Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.
    Chi F; Chen L; Wang C; Li L; Sun X; Xu Y; Ma T; Liu K; Ma X; Shu X
    Bioorg Chem; 2020 Jan; 95():103542. PubMed ID: 31918398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
    Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
    ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
    Norman P
    Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
    Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
    Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques.
    Wang JL; Cheng LP; Wang TC; Deng W; Wu FH
    J Mol Graph Model; 2017 Mar; 72():178-186. PubMed ID: 28107751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
    Forster M; Gehringer M; Laufer SA
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3.
    Nakajima Y; Tojo T; Morita M; Hatanaka K; Shirakami S; Tanaka A; Sasaki H; Nakai K; Mukoyoshi K; Hamaguchi H; Takahashi F; Moritomo A; Higashi Y; Inoue T
    Chem Pharm Bull (Tokyo); 2015; 63(5):341-53. PubMed ID: 25786493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors.
    Su W; Chen Z; Liu M; He R; Liu C; Li R; Gao M; Zheng M; Tu Z; Zhang Z; Xu T
    Bioorg Med Chem Lett; 2022 May; 64():128680. PubMed ID: 35306167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
    Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
    Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
    Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
    J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.